CoChat
Sign Up
Cited by 4,830Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 610 of the 610 references it cites were found in a registry or an index.

Antithrombotic Therapy for VTE Disease

Kearon, Clive, Akl, Elie A., Ornelas, Joseph, Blaivas, Allen, Jimenez, David, Bounameaux, Henri, Huisman, Menno, King, Christopher S., Morris, Timothy A., Sood, Namita, Stevens, Scott M., Vintch, Janine R.E., Wells, Philip, Woller, Scott C., Moores, Lisa·2016·Chest
DOI 10.1016/j.chest.2015.11.026
Open this paper in CoChat — free account

Abstract

Background We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics.Methods We generate strong (Grade 1) and weak (Grade 2) recommendations based on high- (Grade A), moderate- (Grade B), and low- (Grade C) quality evidence.Results For VTE and no cancer, as long-term anticoagulant therapy, we suggest dabigatran (Grade 2B), rivaroxaban (Grade 2B), apixaban (Grade 2B), or edoxaban (Grade 2B) over vitamin K antagonist (VKA) therapy, and suggest VKA therapy over low-molecular-weight heparin (LMWH; Grade 2C). For VTE and cancer, we suggest LMWH over VKA (Grade 2B), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C), or edoxaban (Grade 2C). We have not changed recommendations for who should stop anticoagulation at 3 months or receive extended therapy. For VTE treated with anticoagulants, we recommend against an inferior vena cava filter (Grade 1B). For DVT, we suggest not using compression stockings routinely to prevent PTS (Grade 2B). For subsegmental pulmonary embolism and no proximal DVT, we suggest clinical surveillance over anticoagulation with a low risk of recurrent VTE (Grade 2C), and anticoagulation over clinical surveillance with a high risk (Grade 2C). We suggest thrombolytic therapy for pulmonary embolism with hypotension (Grade 2B), and systemic therapy over catheter-directed thrombolysis (Grade 2C). For recurrent VTE on a non-LMWH anticoagulant, we suggest LMWH (Grade 2C); for recurrent VTE on LMWH, we suggest increasing the LMWH dose (Grade 2C).Conclusions Of 54 recommendations included in the 30 statements, 20 were strong and none was based on high-quality evidence, highlighting the need for further research.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.chest.2015.11.026

Cites

610 of 610 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 401–600 of 610

Flagged first, then by citations

Research works printed but not linked: 3

  1. Kahn, 2014, Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial, Thromb Haemost, 112, 1137
  2. 2012, Pulmonary thromboendarterectomy for treatment of pulmonary hypertension (structured abstract), Health Technol Assess Database
  3. Mismetti, 2015, Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial, JAMA, 313, 1627, 10.1001/jama.2015.3780 · DOI · Paper page

Cited by

Sorted by citations

See all 4,830

Related

See all

Metadata

Authors
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., Stevens, S. M., Vintch, J. R. E., Wells, P., Woller, S. C., & Moores, L.
Affiliations
  • McMaster University (CA)
  • American College of Chest Physicians (US)
  • VA New Jersey Health Care System (US)
  • University of Geneva (CH)
  • Leiden University Medical Center (NL)
  • Virginia Commonwealth University (US)
  • University of California San Diego (US)
  • The Ohio State University (US)
  • University of Utah (US)
  • Harbor–UCLA Medical Center (US)
  • University of Ottawa (CA)
  • Uniformed Services University of the Health Sciences (US)
Corresponding author
Akl, Elie A.
ORCID
Venue
Chest
Publisher
Elsevier BV
Published
2016-02
Volume
149
Issue
2
Pages
315-352
ISSN
0012-3692 (ISSN-L)
DOI
10.1016/j.chest.2015.11.026
OpenAlex
W2225937646
Cited by
4,830
References
610
Citations by year
2026: 173 · 2025: 244 · 2024: 270 · 2023: 321 · 2022: 420 · 2021: 630 · 2020: 697 · 2019: 607 · 2018: 621 · 2017: 530 · 2016: 244
FWCI
627.82
Type
journal article
Language
en
Update notices
erratum (2016-10-01)
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • CHEST Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
American College of Chest Physicians
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
venous thromboembolism, antithrombotic therapy, anticoagulation, dabigatran, rivaroxaban, apixaban, edoxaban, vitamin K antagonists, low molecular weight heparin, cancer-associated thrombosis, inferior vena cava filter, post-thrombotic syndrome, compression stockings, subsegmental pulmonary embolism, thrombolysis, recurrent venous thromboembolism, catheter-directed thrombolysis
MeSH terms
Drug Administration Schedule, Fibrinolytic Agents, Humans, Societies, Medical, Evidence-Based Medicine, International Normalized Ratio, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review